Literature DB >> 10074888

Reference values of urinary excretion of cystine and dibasic aminoacids: classification of patients with cystinuria in the Valencian Community, Spain.

M Guillén1, D Corella, M L Cabello, A M García, J Hernández-Yago.   

Abstract

OBJECTIVE: Cystinuria is an autosomal-recessive disorder of the kidneys and small intestine affecting a luminal transport mechanism shared by cystine, ornithine, arginine, and lysine. Three different types of cystinuria can be distinguished according to the excretion of these amino acids in urine samples. We propose cutoff values from our population as references and we present a classification of cystinuric patients using quantitative amino acid chromatography in first morning urine samples. DESIGN AND METHODS: A random sample of forty healthy subjects belonging to general population of the Valencian Community were selected as control subjects. Cystine, lysine, arginine, and ornithine were quantified by reverse-phase HPLC. Seventy-two subjects, diagnosed previously as cystinuric by the cyanide-nitroprusside test were classified. Probands excreting more than 113.12 micromol cystine per mmol of creatinine (i.e., 1,000 micromol cystine per gram of creatinine) were classified as homozygotes. Parents of homozygotes in whom excretion of amino acids were normal were classified as heterozygotes type I. Those probands showing the excretion of at least one amino acid and the sum of urinary cystine plus the basic amino acids higher than the corresponding references ranges in our population were classified as heterozygotes type II or type III (heterozygotes non-type 1).
RESULTS: We identified 24 homozygotes, 39 non-type I heterozygotes and 3 type I heterozygotes. The remaining 6 probands could not be classified. Means for cystine, lysine, arginine ornithine and their sum in homozygotes and heterozygotes non-type I were significantly (p < 0.001) in excess of the respective reference ranges. Moreover, means values in homozygotes were statistically different (p < 0.001) from heterozygotes non-type I.
CONCLUSION: Urinary excretion of cystine per mmol creatinine allow us to distinguish heterozygotes from homozygotes. However, the best discriminator to distinguish non-type I heterozygotes from normal population might be the excretion of lysine per mmol creatinine. Additional studies including characterization of appropriate haplotypes should be carried out for a more precise identification of types of cystinuria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074888     DOI: 10.1016/s0009-9120(98)00087-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Acute renal failure due to bilateral pieloureteral stone impaction in a 10-month-old boy.

Authors:  Gabriel Miguel Cara Fuentes; Laura Espinosa Roman; Marta Melgosa Hijosa; Mercedes Navarro Torres
Journal:  Clin Exp Nephrol       Date:  2010-05-13       Impact factor: 2.801

Review 2.  Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.

Authors:  Thomas Knoll; Antonia Zöllner; Gunnar Wendt-Nordahl; Maurice Stephan Michel; Peter Alken
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

Review 3.  Pathophysiology and treatment of cystinuria.

Authors:  Josep Chillarón; Mariona Font-Llitjós; Joana Fort; Antonio Zorzano; David S Goldfarb; Virginia Nunes; Manuel Palacín
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

Review 4.  [Nephrolithiasis and nephrocalcinosis in children and adolescents].

Authors:  Bernd Hoppe; Cristina Martin-Higueras; Nina Younsi; Raimund Stein
Journal:  Urologie       Date:  2022-07-08

Review 5.  Precision medicine in renal stone-formers.

Authors:  Fay Hill; John A Sayer
Journal:  Urolithiasis       Date:  2018-11-20       Impact factor: 3.436

6.  Non-type I cystinuria associated with mental retardation and ataxia in a Korean boy with a new missence mutation(G173R) in the SLC7A9 gene.

Authors:  Eun Ha Lee; Yeun Hee Kim; Jin Soon Hwang; Sung Hwan Kim
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.